Viking Therapeutics (VKTX) Earning Somewhat Favorable Media Coverage, Analysis Shows

News coverage about Viking Therapeutics (NASDAQ:VKTX) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Viking Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.4162501219837 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the headlines that may have effected Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

Shares of VKTX traded up $0.02 during trading hours on Friday, hitting $4.41. 427,855 shares of the company were exchanged, compared to its average volume of 799,394. The firm has a market cap of $224.46, a PE ratio of -5.58 and a beta of 2.09. Viking Therapeutics has a one year low of $0.88 and a one year high of $7.36.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Wednesday, March 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04. equities research analysts expect that Viking Therapeutics will post -0.44 EPS for the current fiscal year.

Several equities research analysts have recently weighed in on the company. BidaskClub raised Viking Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 7th. Maxim Group reissued a “buy” rating and set a $8.00 price objective on shares of Viking Therapeutics in a research note on Friday, February 2nd. Roth Capital set a $8.00 price objective on Viking Therapeutics and gave the stock a “buy” rating in a research note on Thursday, March 8th. HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Viking Therapeutics in a research note on Monday, March 26th. Finally, ValuEngine raised Viking Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $9.00.

TRADEMARK VIOLATION NOTICE: “Viking Therapeutics (VKTX) Earning Somewhat Favorable Media Coverage, Analysis Shows” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3341298/viking-therapeutics-vktx-earning-somewhat-favorable-media-coverage-analysis-shows.html.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Insider Buying and Selling by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

ValuEngine Lowers First Mid-Illinois Bancshares  to Hold
ValuEngine Lowers First Mid-Illinois Bancshares to Hold
Etsy  Given New $23.00 Price Target at Morgan Stanley
Etsy Given New $23.00 Price Target at Morgan Stanley
Dropbox  Now Covered by Bank of America
Dropbox Now Covered by Bank of America
Encore Wire  Given News Sentiment Rating of 0.04
Encore Wire Given News Sentiment Rating of 0.04
Redwood Trust  Getting Somewhat Positive Press Coverage, Report Shows
Redwood Trust Getting Somewhat Positive Press Coverage, Report Shows
UBS Reiterates “$75.00” Price Target for CSX
UBS Reiterates “$75.00” Price Target for CSX


Leave a Reply

© 2006-2018 Ticker Report. Google+.